"The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer.
Thyroid cancer is a cancerous growth of the thyroid gland, which is located i"...
KYTRIL Injection is a serotonin-3 (5-HT3) receptor antagonist indicated for:
- The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
- The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, KYTRIL Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.
DOSAGE AND ADMINISTRATION
Prevention of Chemotherapy-Induced Nausea and Vomiting
The recommended dosage for KYTRIL Injection is 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given.
KYTRIL Injection may be administered intravenously either undiluted over 30 seconds, or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes.
Intravenous infusion of KYTRIL Injection should be prepared at the time of administration. However, KYTRIL Injection has been shown to be stable for at least 24 hours when diluted in 0.9% Sodium Chloride or 5% Dextrose and stored at room temperature under normal lighting conditions.
As a general precaution, KYTRIL Injection should not be mixed in solution with other drugs. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.
The recommended dose in pediatric patients 2 to 16 years of age is 10 mcg/kg [see Clinical Studies]. Pediatric patients under 2 years of age have not been studied.
Prevention and Treatment of Postoperative Nausea and Vomiting
The recommended dosage for prevention of postoperative nausea and vomiting is 1 mg of KYTRIL, undiluted, administered intravenously over 30 seconds, before induction of anesthesia or immediately before reversal of anesthesia.
The recommended dosage for the treatment of nausea and/or vomiting after surgery is 1 mg of KYTRIL, undiluted, administered intravenously over 30 seconds.
Dosage Forms and Strengths
Single-Use Vials for Injection: 1 mg/mL, 0.1 mg/mL
Multi-Use Vials for Injection: 4 mg/4 mL
KYTRIL Injection, 1 mg/mL (free base), is supplied in 1 mL Single-Use Vials and 4 mg/4 mL Multi-Use Vials. Contains benzyl alcohol.
NDC 0004-0239-09 (package of 1 Single-Use Vial)
NDC 0004-0240-09 (package of 1 Multi-Use Vial)
KYTRIL Injection, 0.1 mg/mL (free base), is supplied in 1 mL Single-Use Vials. Contains no preservative.
NDC 0004-0242-08 (package of 5 Single-Use Vials)
Store single-use vials and multi-use vials at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]
Once the multi-use vial is penetrated, its contents should be used within 30 days. Do not freeze. Protect from light.
Distributed by: Genentech USA, Inc. A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94QSO-4990.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/22/2011
Additional Kytril Injection Information
Kytril Injection - User Reviews
Kytril Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.